当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2010年第30期 > 正文
编号:11975052
脾氨肽口服冻干粉对小儿肺炎支原体感染的免疫学影响(1)
http://www.100md.com 2010年10月25日 谭国明,杜启鹏
第1页

    参见附件(2178KB,3页)。

     [摘要] 目的:观察脾氨肽口服冻干粉对小儿肺炎支原体感染的疗效及免疫学影响。方法:将入选的78例感染小儿肺炎支原体的患儿按要求随机分为两组,对照组38例给予常规治疗,观察组40例则在常规治疗的基础上给予脾氨肽口服冻干粉治疗,治疗前后分别测定患儿T细胞亚群、免疫球蛋白及补体等变化情况。结果:两组总有效率分别为95.00%和81.58%,差异有统计学意义(P<0.05),观察组的疗效优于对照组。观察组免疫学指标CD3、CD4、CD4/CD8、IgG、IgA均明显升高(P<0.01),CD8、IgM、C3无明显变化(P>0.05)。结论:脾氨肽口服冻干粉能够促进小儿肺炎支原体感染后的康复,降低复发频率,对防治小儿肺炎支原体感染有一定的帮助。

    [关键词] 肺炎支原体感染;脾氨肽口服冻干粉;免疫功能

    [中图分类号] R563.1 [文献标识码]A [文章编号]1674-4721(2010)10(c)-019-03

    Curative effect and immunologic effect of Spleen Aminopeptide Oral Lyophilized Powder on mycoplasma pneumoniae infection

    TAN Guoming, DU Qipeng

    (Department of Pediatrics, Nanhai Traditional Medicine Hospital of Foshan City, Guangdong Province, Foshan 528200, China)

    [Abstract] Objective: To observe the immunologic effect of Spleen Aminopeptide Oral Lyophilized Powderon mycoplasma pneumoniae (MP) infection. Methods: 78 cases of children with MP infection were divided into two groups randomly. The control group (38 cases) was treated with routine therapy. The treatment group (40 cases) was treated with Spleen Aminopeptide Oral Lyophilized Powder based on routine therapy for 20 days. T cell subgroup, immunoglobulin and addiment were determined before and after treatment. Results: Total effective rates in the treatment group and the control group were 95.00% and 81.58% respectively. The therapeutic efficacy of treatment group was significantly higher than that of control group. In treatment group, immunologic indexes such as CD3, CD4, CD4/CD8, IgG and IgA increased significantly (P<0.01), except CD8, IgM, C3 (P>0.05). Conclusion: Spleen Aminopeptide Oral Lyophilized Powder can promote the recovery of MP infection, and reduce chance of recurrent infection, and so that improve the prevention and treatment of MP infection.

    [Key words] Mycoplasma pneumoniae infection; Spleen Aminopeptide Oral Lyophilized Powder; Immulologic function

    肺炎支原体(mycoplasma pneumoniae,MP)是呼吸道感染的常见病原体之一,肺炎支原体感染的患儿以学龄儿童为主[1],高发年龄为5岁以上,婴幼儿也可感染。目前认为,MP感染的年龄有低龄化趋势[2],它不但可以引起小儿呼吸道感染,还可以引起其他脏器损伤[3]。其发病机制不完全清楚,多数认为与MP的直接侵入、免疫介入和毒素有关;免疫因素起着重要的作用 ......

您现在查看是摘要介绍页,详见PDF附件(2178KB,3页)